Evidence map›Paper›PMID 26837242›Full record

ArticleHuman vaccines & immunotherapeutics2016

Induction of protective neutralizing antibody responses against botulinum neurotoxin serotype C using plasmid carried by PLGA nanoparticles.

Tinashe B Ruwona, Haiyue Xu, Junwei Li, Diana Diaz-Arévalo, Amit Kumar, Mingtao Zeng, Zhengrong Cui

Open access · bronzeAbstract read
In one paragraph

Article in Human vaccines & immunotherapeutics, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 100% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 7 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Tinashe B Ruwonaa College of Pharmacy, Pharmaceutics Division, The University of Texas at Austin , Austin , TX , USA.
Haiyue Xua College of Pharmacy, Pharmaceutics Division, The University of Texas at Austin , Austin , TX , USA.
Junwei Lib Department of Biomedical Sciences , Center of Emphasis in Infectious Diseases, Texas Tech University Health Sciences Center El Paso , El Paso , TX , USA.
Diana Diaz-Arévalob Department of Biomedical Sciences , Center of Emphasis in Infectious Diseases, Texas Tech University Health Sciences Center El Paso , El Paso , TX , USA.
Amit Kumara College of Pharmacy, Pharmaceutics Division, The University of Texas at Austin , Austin , TX , USA.
Mingtao Zengb Department of Biomedical Sciences , Center of Emphasis in Infectious Diseases, Texas Tech University Health Sciences Center El Paso , El Paso , TX , USA.
Zhengrong Cuia College of Pharmacy, Pharmaceutics Division, The University of Texas at Austin , Austin , TX , USA.
The University of Texas at Austin · USTexas Tech University · US

Funding

Topical DNA immunization by modifying the hair follicle cycleR01AI078304 · NIAID · UNIVERSITY OF TEXAS AT AUSTIN · PI CUI, ZHENGRONG · 2008 to 2011
$1.4M
An innovative approach to improve the activity of an aluminum-containing adjuvantR21AI105789 · NIAID · UNIVERSITY OF TEXAS AT AUSTIN · PI CUI, ZHENGRONG · 2013 to 2014
$424k
NIAID NIH HHS R01 AI078304NIAID NIH HHS R21 AI105789
6 · The paper itself

Abstract

Botulinum neurotoxin (BoNT) is a lethal neurotoxin, for which there is currently not an approved vaccine. Recent efforts in developing vaccine candidates against botulism have been directed at the heavy chain fragment of BoNT, because antibodies against this region have been shown to prevent BoNT from binding to its receptor and thus to nerve cell surface, offering protection against BoNT intoxication. In the present study, it was shown that immunization with plasmid DNA that encodes the 50 KDa C-terminal fragment of the heavy chain of BoNT serotype C (i.e., BoNT/C-Hc50) and is carried by cationic poly (lactic-co-glycolic) acid (PLGA) nanoparticles induces stronger BoNT/C-specific antibody responses, as compared to immunization with the plasmid alone. Importantly, the antibodies have BoNT/C-neutralizing activity, protecting the immunized mice from a lethal dose of BoNT/C challenge. A plasmid DNA vaccine encoding the Hc50 fragments of BoNT serotypes that cause human botulism may represent a viable vaccine candidate for protecting against botulinum neurotoxin intoxication.

Indexed as

Lactic AcidNanoparticlesPolyglycolic AcidAnimalsAntibodies, BacterialAntibodies, NeutralizingBacterial VaccinesBotulinum ToxinsBotulismHumansImmunizationImmunoglobulin GInjections, IntramuscularMicePlasmidsPolylactic Acid-Polyglycolic Acid CopolymerAntibodies, BacterialAntibodies, NeutralizingBacterial VaccinesBotulinum Toxinsbotulinum toxin type CImmunoglobulin GLactic AcidPolyglycolic AcidPolylactic Acid-Polyglycolic Acid CopolymerVaccines, DNAantibody responsesbotulinum neurotoxinmouse survivalPLGA nanoparticles

Identifiers

PMID26837242
PMCPMC4963044
OpenAlexW2257029001

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.